Clinical efficacy of fecal microbiota transplantation for patients with small intestinal bacterial overgrowth: a randomized, placebo-controlled clinic study

BMC Gastroenterol. 2021 Feb 6;21(1):54. doi: 10.1186/s12876-021-01630-x.

Abstract

Background: Small intestinal bacterial overgrowth (SIBO) is characterized by the condition that bacteria overgrowth in the small intestine. Fecal microbiota transplantation (FMT) has been applied as an effective tool for reestablishing the structure of gut microbiota. However, whether FMT could be applied as a routine SIBO treatment has not been investigated.

Methods: In this trial, 55 SIBO patients were enrolled. All participants were randomized in two groups, and were given FMT capsule or placebo capsules once a week for 4 consecutive weeks. Measurements including the lactulose hydrogen breath test gastrointestinal symptoms, as well as fecal microbiota diversity were assessed before and after FMT therapy.

Results: Gastrointestinal symptoms significantly improved in SIBO patients after treatment with FMT compared to participants in placebo group. The gut microbiota diversity of FMT group had a significant increase, while placebo group showed none.

Conclusions: This study suggests that applying FMT for patients with SIBO can alleviate gastrointestinal symptoms, indicating that FMT may be a promising and novel therapeutic regimen for SIBO. Trial registry This study was retrospectively registered with the Chinese Clinical Trial registry on 2019.7.10 (ID: ChiCTR1900024409, http://www.chictr.org.cn ).

Keywords: Fecal microbiota transplantation; Lactulose breath test; Small intestinal bacterial overgrowth; Therapeutic efficacy.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Bacterial Infections*
  • Fecal Microbiota Transplantation
  • Gastrointestinal Microbiome*
  • Humans
  • Lactulose
  • Treatment Outcome

Substances

  • Lactulose